Characteristics of complete responders to interferon among patients with chronic hepatitis C with high serum levels of RNA

Hepatology Research

Volumn 7, Issue 1, 1997, Pages 19-27

  Ide, Tatsuya ^a   Sata, Michio ^a   Suzuki, Hiroshi ^a   Uchimura, Yasuyo ^a   Shirachi, Miki ^a   Adachi, Norie ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Interferon treatment; Serum HCV RNA level

Indexed keywords

INTERFERON; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; DIAGNOSTIC VALUE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS GENE;

EID: 0030851969     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(97)00367-8     Document Type: Article

References (24)

1. Hoofnagle JH, Di BA. Treatment of chronic type C hepatitis with alpha interferon. Semin Liver Dis 1989; 9: 259-263.
2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506.
3. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
4. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397.
5. Omata M, Ito Y, Yokosuka O, et al. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant alpha-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991; 36: 1217-1222.
6. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
7. Hayashi J, Ohmiya M, Kishihara Y, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151-2156.
8. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-299.
9. Magrin S, Craxi A, Fabiano C, et al. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. J Med Virol 1992; 38: 200-206.
10. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-883.
11. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-1504.
12. Osada T, Iwabuchi S, Takatori M, Yasuda K, Iino S. Significance of serum HCV RNA titer, determined by branched DNA probe assay, in patients with chronic hepatitis C treated with interferon. (in Japanese with English abstract) Acta Hepatol Jpn 1995; 36: 561-567.
13. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
14. Okamoto H, Okada S, Sugi.vama Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990: 60: 215-222.
15. Uredea MS, Horn T, Fultz TJ, et al. Branched chain DNA amplication multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Res 1991; 24: 197-200.
16. Tsukiyama-Kohara K, Yamaguchi K, Maki N, et al. Antigenicities of group I and II hepatitis C virus polypeptides-molecular basis of diagnosis. Virology 1993; 192: 430-437.
17. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-679.
18. Simmonds P, Holmes EC, Cha T-A, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-2399.
19. Wilber JD, Johnson PJ, Dailey PJ, et al. Quantitation of hepatitis C viral RNA in serum or plasma. Proceeding of the American Society for Microbiology General Meeting. 1 992; Abstract S-44: 406.
20. Iino S, Omata M, Kumada H, et al. Quantitation of HCV-RNA by branched DNA probe assay. (in Japanese) J Med Pharma Sci 1993; 30: 327-334.
21. Onto E, Mizokami M, Mizoguchi N, et al. Hepatitis C virus serotype II responds more favorably to interferon - a therapy. J Hepatol 1994; 21: 130-132.
22. Alberti A, Chemello L, Bonetti P, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group. J Hepatol 1993; s123-s126.
23. Saito T, Shinzawa H, Kuboki M, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994; 89: 681-686.
24. Jouet P, Roudot TF, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686-690.